Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
Primary Children's Medical Center
573
mi
from 91732
Salt Lake City, UT
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
Primary Children's Medical Center
573
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
Children's Oncology Group
4
mi
from 91732
Arcadia, CA
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
Children's Oncology Group
4
mi
from 91732
Arcadia, CA
Click here to add this to my saved trials
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
University of California San Francisco Medical Center-Parnassus
41
mi
from 91732
San Francisco, CA
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
University of California San Francisco Medical Center-Parnassus
41
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
Children's Hospital Colorado
825
mi
from 91732
Aurora, CO
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
Children's Hospital Colorado
825
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
Children's Memorial Hospital
1728
mi
from 91732
Chicago, IL
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
Children's Memorial Hospital
1728
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
Indiana University Medical Center
1793
mi
from 91732
Indianapolis, IN
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
Indiana University Medical Center
1793
mi
from 91732
Indianapolis, IN
Click here to add this to my saved trials
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
Riley Hospital for Children
1793
mi
from 91732
Indianapolis, IN
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
Riley Hospital for Children
1793
mi
from 91732
Indianapolis, IN
Click here to add this to my saved trials
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
Johns Hopkins University
2301
mi
from 91732
Baltimore, MD
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
Johns Hopkins University
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
C S Mott Children's Hospital
1931
mi
from 91732
Ann Arbor, MI
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
C S Mott Children's Hospital
1931
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
Washington University School of Medicine
1569
mi
from 91732
Saint Louis, MO
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
Washington University School of Medicine
1569
mi
from 91732
Saint Louis, MO
Click here to add this to my saved trials
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
Univ of Nebraska Med Ctr
1300
mi
from 91732
Omaha, NE
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
Univ of Nebraska Med Ctr
1300
mi
from 91732
Omaha, NE
Click here to add this to my saved trials
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
Hackensack University Medical Center
2430
mi
from 91732
Hackensack, NJ
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
Hackensack University Medical Center
2430
mi
from 91732
Hackensack, NJ
Click here to add this to my saved trials
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
Univ of North Carolina
2194
mi
from 91732
Chapel Hill, NC
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
Univ of North Carolina
2194
mi
from 91732
Chapel Hill, NC
Click here to add this to my saved trials
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated:  3/30/2016
University of Texas Southwestern Medical Center
1225
mi
from 91732
Dallas, TX
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation
Status: Enrolling
Updated: 3/30/2016
University of Texas Southwestern Medical Center
1225
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function
Modifiable Effectors of Renin System Activation: Treatment Evaluation (MODERATE)
Status: Enrolling
Updated:  4/1/2016
Brigham and Women's Hosp
2578
mi
from 91732
Boston, MA
Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function
Modifiable Effectors of Renin System Activation: Treatment Evaluation (MODERATE)
Status: Enrolling
Updated: 4/1/2016
Brigham and Women's Hosp
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
1225
mi
from 91732
Dallas, TX
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
1225
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
357
mi
from 91732
Sedona, AZ
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
357
mi
from 91732
Sedona, AZ
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
427
mi
from 91732
Tucson, AZ
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
427
mi
from 91732
Tucson, AZ
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
19
mi
from 91732
Burbank, CA
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
19
mi
from 91732
Burbank, CA
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
25
mi
from 91732
Rancho Cucamonga, CA
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
25
mi
from 91732
Rancho Cucamonga, CA
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
817
mi
from 91732
Denver, CO
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
817
mi
from 91732
Denver, CO
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
2128
mi
from 91732
Ocala, FL
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
2128
mi
from 91732
Ocala, FL
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
1569
mi
from 91732
Woodbury, MN
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
1569
mi
from 91732
Woodbury, MN
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
1462
mi
from 91732
Columbia, MO
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
1462
mi
from 91732
Columbia, MO
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
208
mi
from 91732
Las Vegas, NV
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
208
mi
from 91732
Las Vegas, NV
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
1763
mi
from 91732
Nashville, TN
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
1763
mi
from 91732
Nashville, TN
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
922
mi
from 91732
Amarillo, TX
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
922
mi
from 91732
Amarillo, TX
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
1213
mi
from 91732
Austin, TX
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
1213
mi
from 91732
Austin, TX
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from 91732
Denton, TX
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from 91732
Denton, TX
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
1297
mi
from 91732
McAllen, TX
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
1297
mi
from 91732
McAllen, TX
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
1315
mi
from 91732
Tyler, TX
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
1315
mi
from 91732
Tyler, TX
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
939
mi
from 91732
Spokane, WA
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
939
mi
from 91732
Spokane, WA
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
874
mi
from 91732
Yakima, WA
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
874
mi
from 91732
Yakima, WA
Click here to add this to my saved trials
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated:  4/4/2016
Clinical Research Facility
1784
mi
from 91732
Birmingham, AL
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated: 4/4/2016
Clinical Research Facility
1784
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated:  4/4/2016
Clinical Research Facility
352
mi
from 91732
Scottsdale, AZ
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated: 4/4/2016
Clinical Research Facility
352
mi
from 91732
Scottsdale, AZ
Click here to add this to my saved trials
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated:  4/4/2016
Clinical Research Facility
1354
mi
from 91732
Fayetteville, AR
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated: 4/4/2016
Clinical Research Facility
1354
mi
from 91732
Fayetteville, AR
Click here to add this to my saved trials
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated:  4/4/2016
Clinical Research Facility
2281
mi
from 91732
Washington,
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated: 4/4/2016
Clinical Research Facility
2281
mi
from 91732
Washington,
Click here to add this to my saved trials
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated:  4/4/2016
Clinical Research Facility
2127
mi
from 91732
Jacksonville, FL
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated: 4/4/2016
Clinical Research Facility
2127
mi
from 91732
Jacksonville, FL
Click here to add this to my saved trials
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated:  4/4/2016
Clinical Research Facility
2573
mi
from 91732
Honolulu, HI
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated: 4/4/2016
Clinical Research Facility
2573
mi
from 91732
Honolulu, HI
Click here to add this to my saved trials
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated:  4/4/2016
Clinical Research Facility
2184
mi
from 91732
Charleston, SC
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated: 4/4/2016
Clinical Research Facility
2184
mi
from 91732
Charleston, SC
Click here to add this to my saved trials
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated:  4/4/2016
Clinical Research Facility
570
mi
from 91732
Salt Lake City, UT
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated: 4/4/2016
Clinical Research Facility
570
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated:  4/4/2016
Clinical Research Facility
1722
mi
from 91732
Milwaukee, WI
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated: 4/4/2016
Clinical Research Facility
1722
mi
from 91732
Milwaukee, WI
Click here to add this to my saved trials
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone in Relapsed/Refractory Patients With Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/4/2016
Roswell Park Cancer Institute
2181
mi
from 91732
Buffalo, NY
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone in Relapsed/Refractory Patients With Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/4/2016
Roswell Park Cancer Institute
2181
mi
from 91732
Buffalo, NY
Click here to add this to my saved trials
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone in Relapsed/Refractory Patients With Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/4/2016
Emory University/Winship Cancer Institute
1922
mi
from 91732
Atlanta, GA
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone in Relapsed/Refractory Patients With Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/4/2016
Emory University/Winship Cancer Institute
1922
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated:  4/4/2016
Winship Cancer Institute at Emory University
1922
mi
from 91732
Atlanta, GA
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated: 4/4/2016
Winship Cancer Institute at Emory University
1922
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated:  4/4/2016
Columbia University Medical Center
2432
mi
from 91732
New York, NY
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated: 4/4/2016
Columbia University Medical Center
2432
mi
from 91732
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated:  4/4/2016
Bon Secours St. Francis Hospital
2017
mi
from 91732
Greenville, SC
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated: 4/4/2016
Bon Secours St. Francis Hospital
2017
mi
from 91732
Greenville, SC
Click here to add this to my saved trials
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated:  4/4/2016
Mayo Clinic
358
mi
from 91732
Scottsdale, AZ
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated: 4/4/2016
Mayo Clinic
358
mi
from 91732
Scottsdale, AZ
Click here to add this to my saved trials
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated:  4/4/2016
The Mayo Clinic
1524
mi
from 91732
Rochester, MN
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated: 4/4/2016
The Mayo Clinic
1524
mi
from 91732
Rochester, MN
Click here to add this to my saved trials
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia
Phase I Study of the Combination of Midostaurin, Bortezomib, and Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/5/2016
Ohio State University Medical Center
1959
mi
from 91732
Columbus, OH
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia
Phase I Study of the Combination of Midostaurin, Bortezomib, and Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/5/2016
Ohio State University Medical Center
1959
mi
from 91732
Columbus, OH
Click here to add this to my saved trials